6 Reasons Why You Should Get An Online Healthcare Master’s Degree

In the healthcare field, the days of graduating with a bachelor’s and landing a job with room for continuous growth have passed. Yes, there are exceptions, but typically not the norm. In today’s cutthroat industry with technology taking jobs, it is becoming necessary to go one step further in distinguishing yourself from the pack. How do you do that? By attaining a master’s degree to set a solid foundation for professional growth.

So now you wonder, will the academic, personal, and financial rigor earning a graduate degree pay off?

Here are 6 reasons why a Master’s in Healthcare Services Administration is an investment in yourself, your career, and your future.

1. Increase Your Job Prospects

An M.S. in Healthcare Services Administration opens doors, and the general fact is that higher salaries are typically bestowed upon professions that require more specialized skills with greater responsibilities. Having a master’s will inherently be more financially lucrative, making you applicable for managerial and directorial positions.

2. So you want to change your career…

After receiving a bachelor degree, you went out into the world and spent a few years absorbed in our industry, only to realize that in order to move up, or change careers, you need something to set you apart. If you are looking to jumpstart a new career, increase your salary, have more options down the road, consider our M.S. program. You can find more information about us, click here.

3. Return on Investment

As a leader in this industry and your community, you need to constantly be thinking ahead and the added value of programs and partnerships you get yourself and your team involved in. So what is in it for you by getting this degree? When considering higher education, it is wise to calculate the return on investment based on industry data. According to the recently released Bureau of Labor Statistics report, the profession of pharmacy is only expected to grow incrementally between now and 2026, but Healthcare Administration is growing at a much faster than average rate. Did you know that you can earn your Masters in Health Services Administration in just five semesters?

4. Our Graduate Courses are Far More Stimulating

Undergraduate programs cover a wide variety of subjects, some more generalized and others more topic specific. Graduate level courses, on the other hand, are entirely concentrated on your particular interest in the field you have elected to pursue. Many of our students love the practicality of our program and we have industry renowned professors guiding you through these courses.

5. Financial assistance: Where there is a will, there is always a way

Research your options. For our specific Master’s program, members of national pharmacy associations, to federal agency employees (including active-duty military) and to pharmacy residents are offered in-state tuition. All members of Wyoming Pharmacy Association receive a full discount on the first two-credit course, so that the full course tuition of $1,650 will be waived for that course. This is a way for you, as the student, to try the program with no tuition cost for the first course. All students are eligible to join WPhAPlease click here and select the most appropriate member type. If no other member type applies to you, then select “staff member” as your member type. We also have a variety of financial solutions for corporate partners looking to partner with higher learning institutions to provide options to their staff. If you are a corporate partner interested in more information, please feel free to contact asuderma@uwyo.edu for more information.

6. You can work in the comfort of your own home. 

Gone are the days where you have to pick a master’s program that is close to your workplace and young and growing family. With our online program, you have the ability to enjoy our courses anywhere in the world, as long as you have adequate wi-fi. Although, we are not able to offer this program internationally yet, it doesn’t mean that you can’t vacation to Bali from the United States and log in for our Sunday evening class.

To apply to our program, please click here.

For more information about our program, click here.

To learn more about our accredited institution, you can check out the home page of the University of Wyoming.

Graduate Spotlight: Dr. Rashid Kazerooni, Botulinum Toxin Type A Overdoses

Dr. Rashid Kazerooni, PharmD, MS, BCPS, is a Medical Science Liaison at Merz North America. Dr. Kazerooni is among the first graduates of the University of Wyoming’s 2016-2018 MSHSA program and we couldn’t more proud of his independent project, Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database, being published.


© Springer International Publishing AG, part of Springer Nature 2018


Published literature on overdoses related to botulinum toxin A (BtxA) agents is scarce.


The aim of this study was to assess the BtxA drug class’ respective agents for associations with overdose.


United States Food and Drug Administration (FDA) adverse event reporting system (FAERS) database was utilized to search for overdoses. The analysis was conducted on data between second quarter 2014 and third quarter 2017. BtxA cases were included when they were considered the “Primary Suspect” drug. Overdose was defined as presence of ‘overdose’ being reported as an adverse event. Primary outcome was incidence of ‘overdose’ compared within the respective agents. Additionally, a disproportionality analysis was conducted utilizing reporting odds ratio (ROR) versus onabotulinumtoxinA as a referent while controlling for confounding variables.

The full study is published and can be purchased from Springer International Publishing, click here.


A total of 3,837,406 unique adverse events were reported during the study period for all drugs in the FAERS database. Of which, 13,078 were BtxA cases. The rate of adverse events involving overdose for abobotulinumtoxinA (20.2%; 215/1065) was significantly higher than both onabotulinumtoxinA (0.4%; 48/11,323; p < 0.0001) and incobotulinumtoxinA (0.1%; 1/690; p < 0.0001). In the regression analysis, abobotulinumtoxinA (ROR 73.26; 95% CI 51.17–104.90) had a significant association with overdose, whereas incobotulinumtoxinA (ROR 0.73; 95% CI 0.10–5.36) did not, versus the referent onabotulinumtoxinA.


The present analysis showed adverse events of abobotulinumtoxinA were significantly associated with overdose versus the other two BtxA agents. Overdose can be difficult to research, particularly for in-clinic administered drugs. Future studies should venture to confirm these results in new and novel ways.

© Springer International Publishing AG, part of Springer Nature 2018


  1. Ubbink DT, Santema TB, Lapid O. Shared decision-making in cosmetic medicine and aesthetic surgery. Aesthet Surg J. 2016;36(1):NP14-9.CrossRefPubMedGoogle Scholar
  2. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7(2):31–9.PubMedPubMedCentralGoogle Scholar
  3. Allergan, Inc. Botox® (onabotulinumtoxinA) prescribing information. 2018. https://www.allergan.com/assets/pdf/botox_pi.pdf. Accessed 10 Mar 2018.
  4. Allergan, Inc. Botox Cosmetic® (onabotulinumtoxinA) prescribing information. 2018. https://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf. Accessed 10 Mar 2018.
  5. Ipsen Biopharm Ltd. Dysport® (abobotulinumtoxinA) prescribing information. 2018. https://www.dysport.com/docs/pdfs/Dysport_Full_Prescribing_Information.pdf. Accessed 10 Mar 2018.
  6. Merz North America, Inc. Xeomin® (incobotulinumtoxinA) prescribing information. 2018. http://www.xeomin.com/wp-content/uploads/xeomin-full-prescribing-information.pdf. Accessed 10 Mar 2018.
  7. Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10:407–10.CrossRefPubMedGoogle Scholar
  8. Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA adverse event reporting system. BMJ Open Diabetes Res Care. 2018;6(1):e000475.CrossRefPubMedPubMedCentralGoogle Scholar
  9. US FDA. FDA adverse event reporting system (FAERS): Latest quarterly data files. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm082193.htm. Accessed 10 Mar 2018.
  10. MedDRA. https://www.meddra.org/. Accessed 10 Mar 2018.
  11. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796–803.CrossRefPubMedPubMedCentralGoogle Scholar
  12. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–36.CrossRefPubMedGoogle Scholar
  13. 14.
    Hauben M, Reich L. Drug-induced pancreatitis: lessons in data mining. Br J Clin Pharmacol. 2004;58:560–2 [PMC free article].CrossRefPubMedPubMedCentralGoogle Scholar
  14. Almenoff J, Tonning JM, Gould AL, et al. Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf. 2005;28:981–1007.CrossRefPubMedGoogle Scholar
  15. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82:157–66.CrossRefPubMedGoogle Scholar
  16. Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14:343–57.CrossRefPubMedGoogle Scholar
  17. Humphrey S. Neurotoxins: evidence for prevention. J Drugs Dermatol. 2017;16(6):s87–90.PubMedGoogle Scholar
  18. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118:201–10.CrossRefPubMedGoogle Scholar
  19. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949–51.CrossRefPubMedGoogle Scholar
  20. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S, NT 201 Blepharospasm Study Team. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm (Vienna). 2006;113(3):303–12.CrossRefGoogle Scholar
  21. Kane MA, Gold MH, Coleman WP 3rd, Jones DH, Tanghetti EA, Alster TS, Rohrer TE, Burgess CM, Shamban AT, Finn E. A Randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. Dermatol Surg. 2015;41(11):1310–9.CrossRefPubMedGoogle Scholar
  22. Sattler G, Callander MJ, Grablowitz D, Walker T, Bee EK, Rzany B, Flynn TC, Carruthers A. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36(Suppl 4):2146–54.CrossRefPubMedGoogle Scholar
  23. Nüssgens Z, Roggenkämper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197–9.CrossRefPubMedGoogle Scholar
  24. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol. 2009;16(3):392–8.CrossRefPubMedGoogle Scholar
  25. Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012;304(2):155–61.CrossRefPubMedGoogle Scholar
  26. 27.
    Weber J. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflamm Res. 1984;6:1–7.Google Scholar
  27. Hoffman KB, Dimbil M, Erdman CB, Tatonetti NP, Overstreet BM. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37:283–94.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13:519–23.CrossRefPubMedGoogle Scholar
  29. US FDA. FDA adverse event reporting system (FAERS) public dashboard. https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm070093.htm. Accessed 10 Mar 2018.